TransCode Therapeutics’ Lead Therapeutic Candidate, TTX-MC138, effectively engaged its Target

(24/7 MARKET NEWS) – TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced this morning  today that its lead therapeutic candidate, TTX-MC138, was delivered to brain tumors and effectively engaged its target in murine models bearing human glioblastoma multiforme (GBM) tumors, the most common and aggressive form of brain cancer.

TransCode Therapeutics is trading at $0.81, up $0.146 (+21.68%), on 2.47M premarket shares traded.

Its 52-week range is $0.4998 to $31.00. It looks like it wants to run to $1.50 and, if it can hold today’s gains, it may be able to reverse its long-term downward trend.

 24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist